Coeptis Therapeutics (NASDAQ:ZSQR) Trading 8.9% Higher – Here’s Why

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) shares were up 8.9% on Wednesday . The company traded as high as $11.52 and last traded at $11.52. 136,898 shares changed hands during trading, a decline of 31% from the average session volume of 197,687 shares. The stock had previously closed at $10.58.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Coeptis Therapeutics Trading Down 8.6%

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25. The business’s 50 day simple moving average is $12.09 and its 200 day simple moving average is $12.62. The stock has a market cap of $565.22 million, a P/E ratio of -4.36 and a beta of -0.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%. The company had revenue of $0.11 million during the quarter.

Institutional Trading of Coeptis Therapeutics

Large investors have recently bought and sold shares of the stock. Yorkville Advisors Global LP bought a new position in shares of Coeptis Therapeutics during the third quarter valued at $140,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after purchasing an additional 2,500 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Coeptis Therapeutics in the 4th quarter worth about $259,000. State Street Corp increased its position in shares of Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after purchasing an additional 6,962 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after purchasing an additional 4,721 shares in the last quarter. 13.88% of the stock is currently owned by institutional investors.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.